Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

CD4+ CD56+ neoplasia: clinical and biological features with emphasis on cytotoxic drug-induced apoptosis and expression of sialyl Lewis X.

Kim SZ, Zollner TM, Schui DK, Chow KU, Sterry W, Kriener S, Hoelzer D, Mitrou PS, Weidmann E.

Leuk Lymphoma. 2003 Feb;44(2):281-9. Review.

PMID:
12688346
2.

Clinical and biologic features of CD4(+)CD56(+) malignancies.

Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drénou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, Sainty D, Sotto MF, Trimoreau F, Béné MC.

Blood. 2002 Mar 1;99(5):1556-63.

3.

CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC).

Petrella T, Dalac S, Maynadié M, Mugneret F, Thomine E, Courville P, Joly P, Lenormand B, Arnould L, Wechsler J, Bagot M, Rieux C, Bosq J, Avril MF, Bernheim A, Molina T, Devidas A, Delfau-Larue MH, Gaulard P, Lambert D.

Am J Surg Pathol. 1999 Feb;23(2):137-46.

PMID:
9989839
4.

A cutaneous agranular CD2- CD4+ CD56+ "lymphoma": report of two cases and review of the literature.

Kameoka J, Ichinohasama R, Tanaka M, Miura I, Tomiya Y, Takahashi S, Yamada M, Ishikawa I, Kadowaki I, Sasaki O, Kimura J, Meguro K, Ooya K, Ito S.

Am J Clin Pathol. 1998 Oct;110(4):478-88. Review.

PMID:
9763034
5.

CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells.

Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC, Larson RS.

Am J Surg Pathol. 2005 Oct;29(10):1274-83.

PMID:
16160468
6.

Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.

Chow KU, Boehrer S, Bojunga J, Stieler M, Rummel MJ, Fauth F, Schneider B, Martin H, Hoelzer D, Weidmann E, Mitrou PS.

Leuk Lymphoma. 2002 Feb;43(2):377-84.

PMID:
11999573
7.

Cutaneous CD4+ CD56+ hematologic malignancies.

Magro CM, Porcu P, Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN.

J Am Acad Dermatol. 2010 Aug;63(2):292-308. doi: 10.1016/j.jaad.2009.08.044. Epub 2010 Jun 11.

PMID:
20541283
8.

Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification.

Kong YY, Dai B, Kong JC, Zhou XY, Lu HF, Shen L, Du X, Shi DR.

Am J Surg Pathol. 2008 Oct;32(10):1495-502. doi: 10.1097/PAS.0b013e31817a9081.

PMID:
18708940
9.

'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes.

Petrella T, Comeau MR, Maynadié M, Couillault G, De Muret A, Maliszewski CR, Dalac S, Durlach A, Galibert L.

Am J Surg Pathol. 2002 Jul;26(7):852-62.

PMID:
12131152
10.

Skin manifestations in CD4+, CD56+ malignancies.

Penven K, Macro M, Salaun V, Comoz F, Reman O, Leroy D, Troussard X, Petrella T, Dompmartin A.

Eur J Dermatol. 2003 Mar-Apr;13(2):161-5.

PMID:
12695132
11.

Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection.

Zhang B, Zong Y, He J, Zhong B, Lin S.

Chin Med J (Engl). 2003 Jun;116(6):913-7.

PMID:
12877806
12.

CD2- CD4+ CD56+ hematodermic/hematolymphoid malignancy.

Kato N, Yasukawa K, Kimura K, Sugawara H, Aoyagi S, Mishina T, Nakata T.

J Am Acad Dermatol. 2001 Feb;44(2):231-8. Review.

PMID:
11174380
13.

Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q.

Mitteldorf C, Bertsch HP, Baumgart M, Haase D, Wulf G, Schön MP, Rosenwald A, Neumann C, Kaune KM.

J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1225-9. doi: 10.1111/j.1468-3083.2010.03922.x. Epub 2010 Nov 25.

PMID:
21923812
14.

CD4+ CD56+ hematodermic neoplasm and plasmacytoid dendritic cell tumor: case report and review of the literature.

Campbell SM, Moad JC, Sammons DL, Zirwas M.

Cutis. 2012 Jun;89(6):278-83. Review.

PMID:
22838092
15.

Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.

Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH.

Blood. 1997 Jun 15;89(12):4501-13. Review.

16.

Cutaneous tumors as the initial presentation of non-T, non-B, nonmyeloid CD4+ CD56+ hematolymphoid malignancy in an adolescent boy.

Fass J, Tichy EH, Kraus EW, Herrick JL, Ehsan A, Peterson J, Grimwood RE.

Pediatr Dermatol. 2005 Jan-Feb;22(1):19-22.

PMID:
15660891
17.

Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.

Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G, et al.

J Immunol. 1994 Mar 15;152(6):3074-87.

PMID:
7511637
18.

Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities.

Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP.

Blood. 2007 Feb 15;109(4):1720-7. Epub 2006 Oct 26.

19.

CD4+ CD56+ hematodermic neoplasm.

Cibull TL, Thomas AB, O'Malley DP, Billings SD.

Am J Dermatopathol. 2007 Feb;29(1):59-61.

PMID:
17284963
20.

Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes.

Kumar S, Krenacs L, Medeiros J, Elenitoba-Johnson KS, Greiner TC, Sorbara L, Kingma DW, Raffeld M, Jaffe ES.

Hum Pathol. 1998 Apr;29(4):397-403.

PMID:
9563791

Supplemental Content

Support Center